| 000 | 01449nab a2200253 c 4500 | ||
|---|---|---|---|
| 999 |
_c147714 _d147714 |
||
| 003 | ES-MaIEF | ||
| 005 | 20230614133105.0 | ||
| 007 | ta | ||
| 008 | 230614t2023 us ||||| |||| 00| 0|eng d | ||
| 040 |
_aES-MaIEF _bspa _cES-MaIEF |
||
| 100 | 1 |
_970726 _aMaini, Luca |
|
| 245 | 0 |
_aReference pricing as a deterrent to entry _bevidence from the European pharmaceutical market _c by Luca Maini and Fabio Pammolli |
|
| 500 | _aResumen. | ||
| 520 | _aExternal reference pricing (ERP), the practice of benchmarking domestic drug prices to foreign prices, generates an incentive for firms to withhold products from low-income countries. Using a novel moment inequality approach, we estimate a structural model to measure how ERP policies affect access to innovative drugs across Europe. We find that ERP increases entry delays in eight low-income European countries by up to one year per drug. The European Union could remove these delays without replacing ERP by compensating firms through lump-sum transfers at the cost of around €18 million per drug. | ||
| 650 | 4 |
_947714 _aMEDICAMENTOS |
|
| 650 | 4 |
_948092 _aPRECIOS |
|
| 650 | 4 |
_947725 _aMERCADO |
|
| 650 | 4 |
_947868 _aOLIGOPOLIOS |
|
| 650 | 4 |
_aEUROPA _943946 |
|
| 650 | 4 |
_aMODELOS ECONOMETRICOS _947776 |
|
| 700 | 1 |
_970727 _aPammolli, Fabio |
|
| 773 | 0 |
_9169674 _oOP 2136/2023/2 _tAmerican Economic Journal : Microeconomics _w(IEF)64890 _x 1945-7669 _g v. 15, n. 2, May 2023, p. 345-383 |
|
| 942 | _cART | ||